-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

An Advancement in Frontline DLBCL and A Fixed-Duration Treatment Option for 3L+ Diffuse Large B-Cell Lymphoma

Sponsor: Genentech
Program: Product Theaters
Monday, December 11, 2023: 8:00 AM-9:00 AM
Room 1B (San Diego Convention Center)
Jamie H. Hirata, PharmD, Genentech
No relevant conflicts of interest to declare.
For In-Person Participants Only
See more of: Product Theaters